Alexion CEO reboots leadership team; Juno adds former Illumina CEO to its board
→ Several executives are being forced out of Alexion by new CEO Ludwig Hanston. CFO David Anderson is resigning in August after only 8 months in the position. Martin MacKay is “retiring” as head of R&D at the end of this year while Clare Carmichael, the chief human resources officer, is out as of June 1. On the same day, Brian Goff will be the company’s new chief commercial officer.
→ Therapix is on the hunt for a new CEO as Elran Haber steps down. “I believe that the Company has reached the point at which it will benefit from U.S.-based leadership,” said Haber. Therapix is focused on repurposing FDA-approved synthetic cannabinoids.
→ President James Scibetta is resigning from New Jersey-based Pacira, effective June 30. The company says it doesn’t intend to replace him.
→ After 14 years with the company in various positions, Novartis global head of strategic alliances H. Martin Seidel is leaving to take on the role of executive vice president of research and development at Boston-based IFM Therapeutics.
→ Juno Therapeutics added former Illumina CEO Jay Flatley to its board of directors. “Jay is one of the great leaders in healthcare of the last two decades,” said Hans Bishop, Juno’s president and CEO, “We are thrilled to have him help guide Juno into our next phase.”
→ Merrimack, in Cambridge, MA, is searching for a new CFO now that Yasir Al-Wakeel will be leaving the company on June 9.